Home > Cardiology > ACC 2019 > Interventional Cardiology > P2Y12 inhibitor monotherapy is a novel antiplatelet strategy after short duration DAPT

P2Y12 inhibitor monotherapy is a novel antiplatelet strategy after short duration DAPT


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ACC 2019
The primary objective of the study by Hahn et al. was to compare P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy (DAPT) with 12 months of DAPT in a broad spectrum of patients receiving current generation drug-eluting stents (DES). The working hypothesis was that P2Y12 inhibitor monotherapy after 3 months of DAPT would be non-inferior to 12 months of DAPT at 12 months after the index procedure [1]. This prospective, multicentre, randomised, open-label, non-inferiority trial included almost 3,000 patients (mean age 65 years, 27% female) who underwent percutaneous coronary intervention (PCI) with DES. They were randomised 1:1 to either DAPT for 3 months (n=1,495) or 12 months (n=1,498). In the former group, after 3 months, aspirin was discontinued and P2Y12 inhibitor monotherapy was continued. Stratification was performed by type of DES used (i.e. cobalt-chromium everolimus-eluting stent vs platinum-chromium everolimus-eluting s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on